arrow_back Back Filing freshness 10-K Q4 FY2026 SEC EDGAR

CHAMPIONS ONCOLOGY, INC.

CSBR
$5.16 ▼ -0.31 (-5.75%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
65 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
31
Health
Poor
Bearish
auto_awesome

Analytical Summary

CHAMPIONS ONCOLOGY, INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth 12.0%
Op. Margin -3.8%
ROIC -17.9%
FCF / Share None
Trailing P/E
Price / Book 18.2x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 5, 2026.

65-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$13.84M
↑ +12.0%
Net Income Profit after all expenses
$-667.00K
↑ +63.7%
Operating Margin Operating profit as % of sales
-3.8%
↓ -126.4% 25th
FCF / Share Free cash flow per share
$-0.10
↑ +30.9%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
20
Returns
18
Cash Quality
94

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 17 years · 65 quarters